Parkinson’s disease and Type 2 diabetes share many common pathophysiological mechanisms.
Insulin signalling modulates a number of cellular processes found to be disrupted in Parkinson’s disease.
A process analogous to peripheral insulin resistance may occur in the brain and contribute to Parkinson’s disease pathology.
Using insulin sensitising drugs to restore insulin signalling may represent a novel therapeutic strategy in Parkinson’s disease.